Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of AL001 (latozinemab) in Frontotemporal Dementia Due to Progranulin Mutations
2019-004066-18Phase 3Active
- Sponsor
- Alector
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in frontotemporal dementia (FTD) comparing AL001 (latozinemab) with Placebo (2 arms). Primary endpoint: CDR plus NACC FTLD-SB change in symptomatic participants. Started Feb 2020; status: active.
02
Drugs
latozinemab
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2019-004066-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004066-18.